Abstract
Biologics have revolutionized the treatment for severe chronic illness and rare diseases. They represent the fastest growing segment in the pharmaceutical industry. However due to high of innovator biologics, the alternate options such as biosimilars have emerged. The impending patent cliff, rising healthcare costs and increasing awareness of biosimilars among physicians are crucial factors which will drive biosimilar uptake in future. Europe has demonstrated its faith in biosimilar treatment and EMA has approved several biosimilars since 2006. Over the years, Ukraine has been a favourable market for branded generics and its evolving regulatory landscape for biosimilar approval is an indication of its preparedness to embrace biosimilars. The current survey attempts to assess the awareness of the biosimilars among Ukrainian physicians.
Highlights
The last couple of decades were characterized by rapid developments in biotechnology with similar biological medicines frequently replacing conventional methods of treating the long-lasting and chronic diseases
The role of biosimilars is buttressed by rising healthcare costs, impending patent cliff and increasing awareness amid key stakeholders [2]
Analysis: Regarding the expected price reduction of biosimilars in comparison to innovators, a majority of respondents required 40-50% lower price for biosimilars than original biologics
Summary
The last couple of decades were characterized by rapid developments in biotechnology with similar biological medicines frequently replacing conventional methods of treating the long-lasting and chronic diseases. The attributes of biosimilars propels more and more countries to revise their national policies in order to make the low-cost biologics a reality today. Ukraine is one of those economies that have recently opened the doors to biologics as a new generation treatment of complex diseases. The pharmaceutical market of Ukraine is characterized by the significant dominance of branded generics [1]. Biosimilars are not considered as generics due to their molecular structure, specificity in manufacturing process and requirement for the additional data to prove similarity with the reference product. Ukraine has special marketing authorization provisions for biosimilars and it differs from that of the standard generic drug authorization [3]. Due to cost-effectiveness and proven attributes of the biosimilars in comparison to the innovator product, these products will serve as the accessible options for the physicians
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
